MARKET

ACAD

ACAD

Acadia Pharmaceuticals Inc
NASDAQ
20.59
-0.17
-0.82%
After Hours: 20.59 0 0.00% 19:30 10/30 EDT
OPEN
20.88
PREV CLOSE
20.76
HIGH
21.01
LOW
20.49
VOLUME
1.14M
TURNOVER
--
52 WEEK HIGH
30.96
52 WEEK LOW
18.39
MARKET CAP
3.55B
P/E (TTM)
9.31
1D
5D
1M
3M
1Y
5Y
1D
Should Earnings Outlook Require Action From Acadia Pharmaceuticals (ACAD) Investors?
Simply Wall St · 1d ago
Tarsus Names Neera Clase Commercial Chief To Expand XDEMVY Reach And Lead Pipeline Planning
NASDAQ · 2d ago
Why Acadia Pharmaceuticals Fell Even As Profit Rose
Simply Wall St · 4d ago
Acadia Pharmaceuticals (ACAD) Stock Dropped, So What Is Driving Attention Now?
Simply Wall St · 5d ago
Weekly Report: what happened at ACAD last week (1019-1023)?
Weekly Report · 5d ago
Press Release: Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026
Dow Jones · 10/21 20:42
Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026
Barchart · 10/21 15:05
Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX) and ACADIA Pharmaceuticals (ACAD)
TipRanks · 10/19 11:30
More
About ACAD
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.

Webull offers ACADIA Pharmaceuticals Inc stock information, including NASDAQ: ACAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACAD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACAD stock methods without spending real money on the virtual paper trading platform.